Jonathan S. Berek - Concepedia

Author

Jonathan S. Berek

Also Known As

&NA;, Berek, J. S, Berek, J.S., Berek, Jonathan, Berek, Jonathan S., E. Burghardt, Elisabeth Avall-Lundqvist, Elisabeth Åvall-Lundqvist, F.M. Muggia, H. Dias

469

Publications

31.1K

Citations

H-Index

181

Concepts

All Affiliations

Stanford University University of California, Los Angeles Gynecologic Oncology Group Princess Margaret Cancer Centre UCLA Jonsson Comprehensive Cancer Center

About

Jonathan S. Berek is an author at Stanford University specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	5	5	206
2	Education	2	2	52
3	Arts	1	1	42
4	Engineering	1	1	26
5	Language Studies	1	1	14

Jonathan S. Berek

182

Publications

22.5K

Citations

H-Index

Page 1

	Year	Citations
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, New England Journal of Medicine	2016	2.4K
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix William A. Peters, P.Y. Liu, Rolland J. Barrett, Journal of Clinical Oncology	2000	2.3K
<scp>FIGO</scp> staging of endometrial cancer: 2023 Jonathan S. Berek, Xavier Matías‐Guiu, Carien L. Creutzberg, International Journal of Gynecology & Obstetrics	2023	811
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Mark F. Brady, Harrison Ball, Jonathan S. Berek American Journal of Obstetrics and Gynecology Surgical OncologyPrimary Cytoreductive SurgeryTumoral PathologyGynecological SurgeryMedicine	1994	670
Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses’ Health Study William H. Parker, Michael S. Broder, Eunice Chang, Obstetrics and Gynecology	2009	617
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller, The Lancet Oncology OncologyMetronomic TherapyGynecologyNiraparib MonotherapyLate-line Treatment	2019	516
Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. William H. Parker, Yao Fu, Jonathan S. Berek PubMed	1994	485
Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study William H. Parker, Diane Feskanich, Michael S. Broder, Obstetrics and Gynecology	2013	435
Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva James M. Heaps, Yao Fu, Fredrick J. Montz, Gynecologic Oncology Surgical OncologyVulvar DiseasesTumoral PathologyGenitourinary CancerSquamous Cell Carcinoma	1990	428
Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. G A Omura, B. Bundy, Jonathan S. Berek, Journal of Clinical Oncology Randomized Clinical TrialSurgical OncologyCancer ManagementGynecologyPathology	1989	327

Page 1